# ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

> **NCT06026332** · — · TERMINATED · sponsor: **Ferring Pharmaceuticals** · enrollment: 202 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** ADSTILADRIN

## Key facts

- **NCT ID:** NCT06026332
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2023-09-15
- **Primary completion:** 2026-01-15
- **Final completion:** 2026-01-15
- **Target enrollment:** 202 (ACTUAL)
- **Why stopped:** An internal audit identified major inconsistencies and missing data in key registry fields, including primary outcomes. These issues mean we can no longer ensure the validity of the primary endpoints.
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06026332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06026332, "ADSTILADRIN Early Utilization and Outcomes in the Real World Setting". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06026332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*